ABSTRACT

Introduction

Eosinophils play a central role in the inflammation of asthma and are the target of new biologic treatments for patients with severe asthma. Biologics targeting the IL-5 pathway have been shown to reduce asthma exacerbations, improve lung function, reduce oral corticosteroid use, and improve quality of life, accompanied by reduced or even eliminated blood eosinophils. Eosinophils have been associated with host protection and tumor growth, raising potential concerns about the consequences of these long-term therapies that reduce or eliminate them.

Areas covered

In this review, we explore the current safety profile of biologics regarding the impact they may have on blood eosinophils, trying to answer the question about any safety consideration.

Expert opinion

Eosinophils have been associated with host protection and tumor growth, raising potential concerns about the consequences of long-term therapies that reduce or eliminate these blood cells.

中文翻译：

---

减少/消除严重哮喘患者的血嗜酸性粒细胞：是否应该考虑安全性？

摘要

介绍

嗜酸性粒细胞在哮喘炎症中起核心作用，是重症哮喘患者新生物治疗的目标。靶向 IL-5 通路的生物制剂已被证明可以减少哮喘发作，改善肺功能，减少口服皮质类固醇的使用，提高生活质量，同时减少甚至消除血嗜酸性粒细胞。嗜酸性粒细胞与宿主保护和肿瘤生长有关，这引起了人们对这些减少或消除它们的长期疗法的后果的潜在担忧。

涵盖的领域

在这篇综述中，我们探讨了当前生物制剂可能对血液嗜酸性粒细胞产生影响的安全性，试图回答有关任何安全性考虑的问题。

专家意见

嗜酸性粒细胞与宿主保护和肿瘤生长有关，这引起了人们对减少或消除这些血细胞的长期治疗后果的潜在担忧。